Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer

“…After screening the title and abstract, there are only 39 publications were left for full-text review. After excluding 17 publications based on full-text analysis, 22 studies [ 8 , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] ] remained for qualitative and quantitative analysis, containing 18% (392/2158) of patients with a BRCA1/2 mutation. To further understand the significance of BRCA1/2 , 22 trials were separated into three phases: neoadjuvant, adjuvant, and progressed.…”

Prognostic value of SPARC in hepatocellular carcinoma: A systematic review and meta-analysis

“…However, the link between the SPARC expression profile and patient survival is a matter of debate and seems to depend on the type of tumor [ 44 , 45 ]. There have been many studies on SPARC expression in patients with pancreatic [ 46 – 48 ], prostate [ 27 , 49 ], lung [ 28 , 50 ], breast [ 27 , 51 ] and other tumors in terms of carcinogenesis, metastasis, and prognosis [ 52 , 53 ]. However, although upregulated SPARC expression is thought to be associated with a favorable outcome [ 54 ], the functional role of SPARC in cancer varies according to tumor type and tissue environment [ 55 ].…”

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022

“…Meanwhile, PCb was found to prolong the relapse-free survival (RFS) of patients with high homologous recombination defect (HRD) scores, highlighting the key role of carboplatin in adjuvant therapy. Recently published clinical research showed no difference in the DFS and OS between the subjects treated with taxanes combined with platinum (TP) and the counterparts with epirubicin, cyclophosphamide and taxanes (ECT) ( 8 ). Taken together, PCb could serve as an effective alternative adjuvant chemotherapy option for patients with operable TNBC, especially those with high HRD scores.…”